Trial Profile

An Open-Label Phase I/IIa Study of the Safety and Efficacy of Melphalan-flufenamide (Melflufen) and Dexamethasone Combination for Patients with Relapsed and/or Relapsed-Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

17 Jun 2021 Results (n=202) of pooled analysis from NCT01897714 and NCT02963493; assessing efficacy of Melflufen and dexamethasone in relapsed/refractory Multiple Myeloma, presented at the 26th Congress of the European Haematology Association
19 May 2021 According to an Oncopeptides media release, pooled analysis of the O-12-M1 and HORIZON studies are published online at ASCO.
19 May 2021 According to an Oncopeptides media release, pooled analysis of the O-12-M1 and HORIZON studies will be presented at the 2021 American Society of Clinical Oncology, ASCO

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com